Drug intelligence / Profile preview

cefepime + doxycycline + vancomycin

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination antibiotic therapy consisting of cefepime (a fourth-generation cephalosporin), doxycycline (a tetracycline antibiotic), and vancomycin (a glycopeptide antibiotic). This combination provides broad-spectrum coverage against various bacterial pathogens including Gram-positive, Gram-negative, and some atypical organisms. The combination has shown enhanced efficacy in treating certain infections compared to monotherapy with any of these antibiotics alone.

Targets

PBP2 (Penicillin-binding protein 2)30S A-site (Bacterial ribosomal 30S A-site)D-Ala-D-Ala (D-Ala-D-Ala terminus)

Beyond the preview

Go deeper on cefepime + doxycycline + vancomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefepime + doxycycline + vancomycin.

Explore the full profile